Manipal Health Enterprises debuts at 11% premium over Rs 590 IPO price

The Development

Manipal Health Enterprises Limited listed on the National Stock Exchange (NSE) and BSE on 5 August 2026, closing a Rs 9,275.22 crore initial public offering. Per listing-day reports across financial media, the stock opened at a premium of about 11% to its issue price of Rs 590, the upper end of the Rs 560 to Rs 590 price band, with BusinessLine reporting the share trading around Rs 651 shortly after the debut. NSE is the designated stock exchange for the offer.

The offer opened on 29 July and closed on 31 July 2026 and was subscribed 4.92 times overall, per exchange subscription data reported at the close. Demand was led by qualified institutional buyers, whose portion was covered 8.25 times; the non-institutional portion was subscribed 1.02 times, while the retail portion drew bids for 93% of the shares reserved for it. Manipal is, by its own account in the offer document, India's largest pan-India multispecialty hospital network by bed capacity. The listing was surfaced via coverage in The Economic Times, while the company, offer and risk detail below is drawn from the red herring prospectus filed with SEBI.

The Company

Manipal Health Enterprises operates a pan-India network of multispecialty hospitals, focused on tertiary and quaternary care across cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences, a grouping the company labels CONGO-R. As of 31 March 2026, it operated 49 hospitals, including six operated-and-managed facilities, with 13,037 licensed beds across 14 states and union territories, and a workforce of 24,240 employees. The company states it served 7.63 million patients in Fiscal 2026 and is the largest pan-India multispecialty hospital chain by bed capacity, citing a CRISIL report.

On its restated consolidated financials, the company discloses total income of Rs 10,520.52 crore in Fiscal 2026, up from Rs 8,362.79 crore in Fiscal 2025 and Rs 6,265.17 crore in Fiscal 2024. Profit for the year was Rs 916.52 crore in Fiscal 2026, lower than the Rs 1,081.67 crore of Fiscal 2025 and above the Rs 533.20 crore of Fiscal 2024, per the RHP. Total borrowings stood at Rs 10,553.43 crore as of 31 March 2026. The promoters, who held 69.86% before the offer, are Dr. Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd, Kangto Investments Pte. Ltd., Imperius Healthcare Investments Pte. Ltd. and Kabru Investments Pte. Ltd.

The Offer Structure

The offer combined a fresh issue of equity shares aggregating Rs 8,000 crore with an offer for sale of up to 21,613,834 shares aggregating Rs 1,275.22 crore, for a total of Rs 9,275.22 crore, per the RHP and exchange record. Each share has a face value of Rs 2 and the price band was set at Rs 560 to Rs 590. The company receives no proceeds from the offer for sale, which flows to the selling shareholders; these include Imperius Healthcare Investments Pte. Ltd. (up to 10,808,861 shares), Manipal Education and Medical Group India Private Limited, TPG SG Magazine Pte. Ltd. and four other investor selling shareholders named in the RHP.

The objects of the fresh issue, as stated in the offer document, are the repayment or prepayment of certain borrowings of subsidiary Manipal Hospitals Private Limited (an estimated Rs 5,552.76 crore from net proceeds), the acquisition of a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (Rs 574 crore), and general corporate purposes. The book-running lead managers were Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India and DBS Bank India; KFin Technologies is the registrar. Readers working through the arithmetic of an allotment can use Oquilia's lumpsum calculator or CAGR calculator, and prior coverage sits on the Oquilia news desk.

Risk Factors

The company sets out its risks in the offer document, and the following are among those it discloses. The RHP lists geographic concentration as a leading risk: Manipal derived 46.40% of its revenue from operations in Fiscal 2026 from hospitals in Karnataka, so disruption or policy change in that state could materially affect the business. The company also discloses specialty concentration, with 64.30% of gross inpatient revenue in Fiscal 2026 coming from the CONGO-R specialties, alongside a dependence on maintaining inpatient admissions and hospital occupancy rates.

Among the risk factors the company discloses is its reliance on insurance and third-party administrators, which accounted for 49.68% of gross inpatient revenue in Fiscal 2026, exposing it to collection and contract risks. The RHP also flags a related-party element: part of the net proceeds is proposed to repay non-convertible debentures issued to DBS Bank Ltd, the parent of DBS Bank India Limited, which is a book-running lead manager deemed an associate of promoter and selling shareholder Imperius Healthcare Investments. The company further discloses exposure to legal claims and regulatory action, including alleged medical negligence, and notes the offer was made under Regulation 6(2) of the SEBI ICDR Regulations as its net tangible assets were below the threshold under Regulation 6(1)(a).

What Happens Next

With listing complete, the shares now trade on the NSE and BSE at prices set by the market rather than the issue price. The company receives only the fresh-issue proceeds of Rs 8,000 crore, which the offer document earmarks for repaying subsidiary borrowings, acquiring the Sahyadri Hospitals minority stake and general corporate purposes; the selling shareholders receive the offer-for-sale proceeds.

From here the standard post-listing mechanics apply. Anchor and pre-issue shareholders are subject to lock-in periods under the SEBI ICDR Regulations, and the company becomes subject to continuous-disclosure obligations such as periodic results and governance filings with the exchanges. The full red herring prospectus, including the complete risk-factors section, remains available on SEBI's website and the exchanges.

FAQ

Should I apply for this IPO?

Oquilia does not make recommendations, and the offer has in any case closed and listed. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges. Read it directly before making any decision.

What was the price band and issue size?

The price band was Rs 560 to Rs 590 per share of face value Rs 2, per the RHP and exchange record. The total offer was Rs 9,275.22 crore, made up of a fresh issue of Rs 8,000 crore and an offer for sale of up to 21,613,834 shares aggregating Rs 1,275.22 crore.

How was the issue subscribed?

Per exchange subscription data reported at the close of the 29 to 31 July window, the offer was subscribed 4.92 times overall. The qualified institutional buyer portion was covered 8.25 times, the non-institutional portion 1.02 times, and the retail portion drew bids for 93% of the shares reserved for it.

What are the objects of the fresh issue?

The offer document states the fresh-issue proceeds are for repaying or prepaying certain borrowings of subsidiary Manipal Hospitals Private Limited (an estimated Rs 5,552.76 crore), acquiring a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (Rs 574 crore), and general corporate purposes. The company receives nothing from the offer for sale.

Where can I read the RHP?

The red herring prospectus is filed with SEBI and available on its website, as well as on the NSE and BSE. It carries the full financials, the objects of the offer and the complete risk-factors section that this report summarises.

This report is based on the red herring prospectus filed with SEBI by Manipal Health Enterprises Limited. It was surfaced via listing coverage in The Economic Times.